vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and EVERSPIN TECHNOLOGIES INC. (MRAM). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $14.9M, roughly 1.3× EVERSPIN TECHNOLOGIES INC.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -2.0%, a 1.2% gap on every dollar of revenue. On growth, EVERSPIN TECHNOLOGIES INC. posted the faster year-over-year revenue change (13.2% vs -25.7%). Over the past eight quarters, EVERSPIN TECHNOLOGIES INC.'s revenue compounded faster (18.2% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Everspin Technologies, Inc. is a publicly traded semiconductor company headquartered in Chandler, Arizona, United States. It develops and manufactures discrete magnetoresistive RAM or magnetoresistive random-access memory (MRAM) products, including Toggle MRAM and Spin-Transfer Torque MRAM (STT-MRAM) product families. It also licenses its technology for use in embedded MRAM (eMRAM) applications, magnetic sensor applications as well as performs backend foundry services for eMRAM.
CTMX vs MRAM — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $14.9M |
| Net Profit | $-154.0K | $-296.0K |
| Gross Margin | — | 52.7% |
| Operating Margin | -6.9% | 29.0% |
| Net Margin | -0.8% | -2.0% |
| Revenue YoY | -25.7% | 13.2% |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.9M | ||
| Q4 25 | — | $14.8M | ||
| Q3 25 | — | $14.1M | ||
| Q2 25 | $18.7M | $13.2M | ||
| Q1 25 | $50.9M | $13.1M | ||
| Q4 24 | $38.1M | $13.2M | ||
| Q3 24 | $33.4M | $12.1M | ||
| Q2 24 | $25.1M | $10.6M |
| Q1 26 | — | $-296.0K | ||
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $54.0K | ||
| Q2 25 | $-154.0K | $-670.0K | ||
| Q1 25 | $23.5M | $-1.2M | ||
| Q4 24 | $18.9M | $1.2M | ||
| Q3 24 | $5.7M | $2.3M | ||
| Q2 24 | $-6.5M | $-2.5M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | — | 50.8% | ||
| Q3 25 | — | 51.3% | ||
| Q2 25 | — | 51.3% | ||
| Q1 25 | — | 51.4% | ||
| Q4 24 | — | 51.3% | ||
| Q3 24 | — | 49.2% | ||
| Q2 24 | — | 49.0% |
| Q1 26 | — | 29.0% | ||
| Q4 25 | — | -7.2% | ||
| Q3 25 | — | -11.0% | ||
| Q2 25 | -6.9% | -14.9% | ||
| Q1 25 | 44.4% | -14.7% | ||
| Q4 24 | 46.4% | -11.8% | ||
| Q3 24 | 12.3% | -17.5% | ||
| Q2 24 | -33.7% | -26.5% |
| Q1 26 | — | -2.0% | ||
| Q4 25 | — | 8.1% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | -0.8% | -5.1% | ||
| Q1 25 | 46.2% | -8.9% | ||
| Q4 24 | 49.6% | 9.2% | ||
| Q3 24 | 17.2% | 18.8% | ||
| Q2 24 | -26.0% | -23.5% |
| Q1 26 | — | $-0.01 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $-0.03 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $0.10 | ||
| Q2 24 | — | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $40.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $70.2M |
| Total Assets | $175.1M | $83.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $40.5M | ||
| Q4 25 | — | $44.5M | ||
| Q3 25 | — | $45.3M | ||
| Q2 25 | $49.0M | $45.0M | ||
| Q1 25 | $47.6M | $42.2M | ||
| Q4 24 | $38.1M | $42.1M | ||
| Q3 24 | $40.6M | $39.6M | ||
| Q2 24 | $43.2M | $36.8M |
| Q1 26 | — | $70.2M | ||
| Q4 25 | — | $68.9M | ||
| Q3 25 | — | $65.8M | ||
| Q2 25 | $119.9M | $64.1M | ||
| Q1 25 | $25.0M | $63.0M | ||
| Q4 24 | $-456.0K | $62.6M | ||
| Q3 24 | $-23.5M | $59.3M | ||
| Q2 24 | $-31.2M | $55.4M |
| Q1 26 | — | $83.2M | ||
| Q4 25 | — | $84.6M | ||
| Q3 25 | — | $80.3M | ||
| Q2 25 | $175.1M | $78.9M | ||
| Q1 25 | $98.5M | $80.2M | ||
| Q4 24 | $120.5M | $77.8M | ||
| Q3 24 | $139.0M | $72.6M | ||
| Q2 24 | $159.2M | $64.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $570.0K |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $570.0K | ||
| Q4 25 | — | $2.6M | ||
| Q3 25 | — | $881.0K | ||
| Q2 25 | $-15.8M | $5.0M | ||
| Q1 25 | $-21.0M | $1.4M | ||
| Q4 24 | $-19.9M | $3.8M | ||
| Q3 24 | $-20.7M | $2.8M | ||
| Q2 24 | $-19.5M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-975.0K | ||
| Q3 25 | — | $543.0K | ||
| Q2 25 | $-15.8M | $3.0M | ||
| Q1 25 | $-21.2M | $527.0K | ||
| Q4 24 | $-20.0M | $2.1M | ||
| Q3 24 | $-20.7M | $2.8M | ||
| Q2 24 | $-19.6M | $1.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | -6.6% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | -84.6% | 22.9% | ||
| Q1 25 | -41.6% | 4.0% | ||
| Q4 24 | -52.5% | 15.8% | ||
| Q3 24 | -62.1% | 22.9% | ||
| Q2 24 | -78.2% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 24.3% | ||
| Q3 25 | — | 2.4% | ||
| Q2 25 | 0.1% | 15.1% | ||
| Q1 25 | 0.2% | 6.9% | ||
| Q4 24 | 0.2% | 13.2% | ||
| Q3 24 | 0.1% | 0.5% | ||
| Q2 24 | 0.4% | 0.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.19× | ||
| Q3 25 | — | 16.31× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | 3.16× | ||
| Q3 24 | -3.61× | 1.25× | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
MRAM
| Product sales | $14.1M | 95% |
| Licensing, royalty, patent, engineering services and other revenue | $772.0K | 5% |
